- Medicenna Therapeutics Corp. (MDNA) reports new encouraging clinical data from its phase 1/2 ABILITY study of MDNA11
- The ABILITY study is designed to assess various doses of IV administered MDNA11 in patients with tumors
- Data shows the development of anti-cancer immune cells behaving as it was designed
- Medicenna is now enrolling patients in the trial’s fourth dose escalation cohort
- Medicenna Therapeutics Corp. (MDNA) is up 5.63 per cent trading at $1.50 per share as of 3:20 p.m. ET
Medicenna Therapeutics Corp. (MDNA) has reported encouraging new clinical data from its phase 1/2 ABILITY study of MDNA11.
The ABILITY study is designed to assess the safety, pharmacokinetics, pharmacodynamics, and anti-tumour activity of various doses of IV administered MDNA11 in patients with advanced, relapsed, or refractory solid tumours.
The trial includes an MDNA11 monotherapy section, as well as a combination part designed to evaluate MDNA11 with a checkpoint inhibitor.
The ABILITY study’s first three cohorts have provided an encouraging initial look at MDNA11’s clinical profile.
The trial’s preliminary data show the development of anti-cancer immune cells behaving precisely as it was designed, providing early clinical validation for the MDNA11 program and the company’s broader Superkine platform.
Dr. Fahar Merchant, President and CEO of Medicenna, stated
“MDNA11-induced increases in both the adaptive and innate population of anti-cancer immune cells are notably greater than those achieved by competing agents, including those with demonstrated clinical activity, when administered equivalent doses based on IL-2 content… This suggests MDNA11 may demonstrate superior efficacy, particularly as we continue to dose escalate in the trial’s subsequent cohorts.”
With this data in hand, Medicenna is now enrolling patients in the trial’s fourth dose-escalation cohort and progressing towards an expected initial update on efficacy data in mid-2022.
About 80 patients are expected to be enrolled in the ABILITY study. Medicenna plans to conduct a dose-expansion phase that will enroll patients with renal cell carcinoma, melanoma, and other solid tumours in monotherapy and combination settings.
“We believe that the ABILITY study’s early results are promising, as they indicate MDNA11 is potently and selectively stimulating proliferation of cancer fighting immune cells in a dose-dependent manner,” continued Dr. Merchant.
Medicenna Therapeutics Corp. (MDNA) is up 5.63 per cent trading at $1.50 per share as of 3:20 p.m. ET.
